| A phase II trial of first-line sorafenib in patients with metastatic renal ... - UroToday |
|
|
UroTodayOur aim was to evaluate first-line treatment of metastatic renal cell carcinoma (mRCC) with sorafenib in patients unwilling to receive immunotherapy or with ... read more |